Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-975-0 | CAS number: 26760-64-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
The repeat dose toxicity of isoamylene has been determined by testing of its main constituent, 2-methyl-2-butene (2M2B), which produced some general systemic effects in rats following repeated exposure. These effects were slight and were most apparent in the high dose animals and only to a small extent in the mid-dose animals. The No Observed Effect Concentration was 1665 mg/m3 (580 ppm).
Key value for chemical safety assessment
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 1 665 mg/m³
Additional information
Oral
No animal or human data are available
Dermal
No animal or human data are available
Inhalation
Animal data
In a combined repeat dose/reproductive/developmental study (OECD 422; HLS, 2004) on 2 -methyl-2 -butene (2M2B; the main component of isoamylene), rats were exposed (whole body) via inhalation to 580, 2000 and 7000 ppm (1665, 5740 and 20090 mg/m3). For the repeated dose phase of the study the exposures were for 6 hr/day, 7 days/week for 28 days.
Bodyweight gain was slightly reduced at the top dose. Slightly longer clotting times were reported at 2,000 ppm (prothrombin time for females) and 7,000 ppm (prothrombin times for both sexes and activated partial thromboplastin times for males). Cholesterol levels were increased among the females exposed to 7,000 ppm, but in the absence of any further effects in the clinical chemistry parameters or the males this finding was considered to be of uncertain biological significance. In the high-dose females pathological changes were reported in the liver, with associated increased organ weight and some minor hypertrophy of centrilobular hepatocytes. There was also a decreased incidence of extramedullary hematopoiesis in the spleen in the high dose animals and an increase in goblet cell hyperplasia in the nasal passages of the high dose males. In addition, a slight increase in severity of myocardial inflammatory heart lesions and in cortical/medullary tubular basophilia in the kidneys was observed in males at ≥2000 ppm.
General systemic effects were reported in this study, but these effects were slight and primarily in those animals exposed to the highest dose and to a lesser extent to those exposed to 2000 ppm. Based on these observations the No Observed Effect Level (NOEC) in this study was concluded to be 580 ppm (1,665 mg/m3).
Human data
No data available
Justification for classification or non-classification
Based on the slight general effects seen in this study with a NOAEC at 1665 mg/m3and LOAEC of 5740 mg/m3, in consideration of the criteria of DSD and (i. e. no adverse effects at ≤1000 mg/m3 in 90 day studies and ≤3000 mg/m3 in 28 days studies) no classification of isoamylene for repeat dose effects is warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
